Table 1

Clinical-pathological parameters of patients with prostate cancer and non-malignant prostate disease

PCA (n = 113)

BPH (n = 17)

normal (n = 6)


serum PSA

< 4 ng/ml

9 (7.9%)

0 (0.0%)

0 (0.0%)

4-10 ng/ml

48 (42.5%)

2 (11.7%)

0 (0.0%)

> 10 ng/ml

48 (42.5%)

2 (11.7%)

0 (0.0%)

n.a.

8 (7.1%)

13 (76.5%)

6 (100%)


digital rectal examination

normal

51 (45.1%)

suspicious

50 (44.2%)

n.a.

12 (10.6%)


pathological stage

pT2

61 (54.0%)

pT3a

33 (29.2%)

pT3b

16 (14.1%)

pT4

3 (2.6%)

seminal vesicle infiltration

18 (15.8%)

lymph node metastasis

9 (7.9%)


Gleason Score

< 7

48 (42.5%)

3 + 4 = 7

11 (9.8%)

4 + 3 = 7

11 (9.8%)

8-10

43 (38.0%)


n.a., not available; PCA, prostate cancer; BPH, benign prostate hyperplasia

Behbahani et al. BMC Urology 2012 12:5   doi:10.1186/1471-2490-12-5

Open Data